Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call

Reuters

27 May

Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call

Pfizer Inc. held its first-quarter 2025 earnings conference call on April 29, 2025, where the company's leadership discussed their latest financial results and strategic priorities. The event was attended by key executives, including Francesca DeMartino, Chief Investor Relations Officer; Dr. Albert Bourla, Chairman and CEO; and Dave Denton, CFO. Analysts from various financial institutions also participated in the call. During the call, Dr. Albert Bourla expressed satisfaction with the company's performance, stating, "We are very pleased with our performance in the first quarter as we continue to execute with focus and discipline on our strategic priorities." The discussion highlighted Pfizer's commitment to maintaining a robust financial standing and the ongoing execution of its strategic initiatives. The call also covered forward-looking statements and emphasized the importance of reviewing the disclaimers and disclosures available on Pfizer's website. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538107658"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538107658\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538107658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538107658","market":"us","top_or_hot":-1,"title":"Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pfizer Inc. held its first-quarter 2025 earnings conference call on April 29, 2025, where the company's leadership discussed their latest financial results and strategic priorities. The event was attended by key executives, including Francesca DeMartino, Chief Investor Relations Officer; Dr. Albert Bourla, Chairman and CEO; and Dave Denton, CFO. Analysts from various financial institutions also participated in the call. During the call, Dr. Albert Bourla expressed satisfaction with the company's performance, stating, \"We are very pleased with our performance in the first quarter as we continue to execute with focus and discipline on our strategic priorities.\" The discussion highlighted Pfizer's commitment to maintaining a robust financial standing and the ongoing execution of its strategic initiatives. The call also covered forward-looking statements and emphasized the importance of reviewing the disclaimers and disclosures available on Pfizer's website. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Inc. Releases Transcript of Q1 2025 Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-27 01:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pfizer Inc. held its first-quarter 2025 earnings conference call on April 29, 2025, where the company's leadership discussed their latest financial results and strategic priorities. The event was attended by key executives, including Francesca DeMartino, Chief Investor Relations Officer; Dr. Albert Bourla, Chairman and CEO; and Dave Denton, CFO. Analysts from various financial institutions also participated in the call. During the call, Dr. Albert Bourla expressed satisfaction with the company's performance, stating, \"We are very pleased with our performance in the first quarter as we continue to execute with focus and discipline on our strategic priorities.\" The discussion highlighted Pfizer's commitment to maintaining a robust financial standing and the ongoing execution of its strategic initiatives. The call also covered forward-looking statements and emphasized the importance of reviewing the disclaimers and disclosures available on Pfizer's website. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDLbvTWmz:1","article_id":"2538107658","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538107658","pubTimestamp":1748280548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pfizer Inc. held its first-quarter 2025 earnings conference call on April 29, 2025, where the company's leadership discussed their latest financial results and strategic priorities. The event was attended by key executives, including Francesca DeMartino, Chief Investor Relations Officer; Dr. Albert Bourla, Chairman and CEO; and Dave Denton, CFO. Analysts from various financial institutions also participated in the call. During the call, Dr. Albert Bourla expressed satisfaction with the company's performance, stating, \"We are very pleased with our performance in the first quarter as we continue to execute with focus and discipline on our strategic priorities.\" The discussion highlighted Pfizer's commitment to maintaining a robust financial standing and the ongoing execution of its strategic initiatives. The call also covered forward-looking statements and emphasized the importance of reviewing the disclaimers and disclosures available on Pfizer's website. The full transcript can be acce","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"辉瑞公司发布2025年第一季度收益看涨期权记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Pfizer Inc. Releases Transcript of Q1 2025 Earnings Call\n    \n\n        Pfizer Inc. held its first-quarter 2025 earnings conference call on April 29, 2025, where the company's leadership discussed their latest financial results and strategic priorities. The event was attended by key executives, including Francesca DeMartino, Chief Investor Relations Officer; Dr. Albert Bourla, Chairman and CEO; and Dave Denton, CFO. Analysts from various financial institutions also participated in the call. During the call, Dr. Albert Bourla expressed satisfaction with the company's performance, stating, \"We are very pleased with our performance in the first quarter as we continue to execute with focus and discipline on our strategic priorities.\" The discussion highlighted Pfizer's commitment to maintaining a robust financial standing and the ongoing execution of its strategic initiatives. The call also covered forward-looking statements and emphasized the importance of reviewing the disclaimers and disclosures available on Pfizer's website. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}